Our writers · the desk
Two writers. One bill.
Two beats, split the way a purchase splits: pricing analyst and consumer-access reporter. Each writer owns one of them, and the same name always covers the same ground, so you know whose reasoning to argue with.
- Byline 01Pricing analyst
Derek Moss
Reads the bill, not the banner, and prints the figure you will actually pay each month.
Beat — What each seller actually bills per month: the fees outside the headline, the prepay terms, and the figure a reader will pay.
All-in monthly pricingMembership and consult feesPrepay and subscription termsPer-vial and per-dose price conversionPromotional versus standing prices
Published here
- Research answers
- 69
- Guides
- 4
- Seller reviews
- 88
- Total
- 161
Latest
- ResearchCompare Peptide Treatment Quotes: What the Monthly Price Leaves OutOctober 2026
- ResearchPeptide Subscription Auto Renewal: What to Confirm Before EnrollmentOctober 2026
- ResearchSermorelin Tablets: What the Oral Form Costs Against the InjectionOctober 2026
- ResearchVyleesi vs Addyi: What Each Costs a Month and Who Each One Is ForOctober 2026
- Byline 02Consumer-access reporter
Jenna Pratt
Reports how prescribing, pharmacies and cancellation actually work, so the price you see is the process you get.
Beat — How to actually get a peptide prescribed: the telehealth visit, the pharmacy, state availability, cancellation and what each step costs.
Telehealth intake and prescribingCompounding pharmacy rulesState availabilityCancellation and refund termsInsurance and cash-pay access
Published here
- Research answers
- 82
- Guides
- 3
- Seller reviews
- 150
- Total
- 235
Latest
- ResearchCompounded Medication Recall: How to Check Your VialOctober 2026
- ResearchFDA Registered vs FDA Approved Pharmacy: What the Claim MeansOctober 2026
- ResearchPeptide Medication Shipping Delays: What to Do Before Using a Warm DeliveryOctober 2026
- ResearchTransfer a Peptide Prescription: What the New Pharmacy NeedsOctober 2026
What a byline here does not claim
Nobody on this desk holds a medical, pharmacy or law license, and no byline pretends to. A made-up title is a cheap way to sell a peptide, so we check receipts instead: each price shows the month it was read, and each dose or rule links to the label, trial or regulator’s page it came from. Hold us to those links.
The methodology explains how a price reaches a board; the editorial policy sets out what we will not claim.